Cunningham Julie L, Craner Julia R, Evans Michele M, Hooten W Michael
Department of Pharmacy, Mayo Clinic College of Medicine, Rochester, MN.
Department of Psychiatry and Psychology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, MN; Department of Psychiatry and Behavioral Medicine, Spectrum Health System, Grand Rapids, MI.
J Pain Res. 2017 Feb 9;10:311-317. doi: 10.2147/JPR.S123487. eCollection 2017.
In the context of widespread opioid use, increased emphasis has been placed on the potentially deleterious effects of concurrent benzodiazepine (BZD) and opioid use. Although use of opioids in chronic pain has been a major focus, BZD use is equally concerning. Thus, the primary aim of this study was to determine the associations between BZD and opioid use in adults with chronic pain upon admission to an outpatient interdisciplinary pain rehabilitation (IPR) program.
The study cohort involved 847 consecutive patients admitted to a 3-week outpatient IPR program from January 2013 through December 2014. Study variables included baseline demographic and clinical characteristics, Center for Epidemiologic Studies-Depression Scale, Pain Catastrophizing Scale, and the pain severity subscale of the Multidimensional Pain Inventory.
Upon admission, 248 (29%) patients were taking BZDs. Patients using BZDs were significantly more likely to use opioids and to be female. Additionally, patients using BZDs had significantly greater depression, pain catastrophizing, and pain severity scores. In univariable logistic regression analysis, opioid use, female sex, and greater scores of depression, pain catastrophizing, and pain severity were significantly associated with BZD use. In multivariable logistic regression analysis adjusted for age, sex, pain duration, opioid use, depression, pain catastrophizing, and pain severity, only female sex and greater depression scores were significantly associated with BZD use.
Among patients participating in an outpatient IPR program, female sex and greater depression scores were associated with BZD use. Results identify a high prevalence of BZD use in patients with chronic pain and reinforce the need to weigh the risks versus benefits when prescribing in this patient population.
在阿片类药物广泛使用的背景下,人们越来越重视苯二氮䓬类药物(BZD)与阿片类药物同时使用的潜在有害影响。虽然阿片类药物在慢性疼痛中的使用一直是主要关注点,但BZD的使用同样令人担忧。因此,本研究的主要目的是确定成年慢性疼痛患者在进入门诊跨学科疼痛康复(IPR)项目时,BZD与阿片类药物使用之间的关联。
研究队列包括2013年1月至2014年12月连续收治的847例参加为期3周门诊IPR项目的患者。研究变量包括基线人口统计学和临床特征、流行病学研究中心抑郁量表、疼痛灾难化量表以及多维疼痛量表的疼痛严重程度分量表。
入院时,248例(29%)患者正在服用BZD。使用BZD的患者更有可能使用阿片类药物,且女性居多。此外,使用BZD的患者抑郁、疼痛灾难化和疼痛严重程度评分显著更高。在单变量逻辑回归分析中,阿片类药物使用、女性性别以及更高的抑郁、疼痛灾难化和疼痛严重程度评分与BZD使用显著相关。在对年龄、性别、疼痛持续时间、阿片类药物使用、抑郁、疼痛灾难化和疼痛严重程度进行校正的多变量逻辑回归分析中,只有女性性别和更高的抑郁评分与BZD使用显著相关。
在参加门诊IPR项目的患者中,女性性别和更高的抑郁评分与BZD使用相关。结果表明慢性疼痛患者中BZD使用的患病率很高,并强调在该患者群体中开处方时权衡风险与益处的必要性。